MEDI4736 in combination with nab-paclitaxel and gemcitabine + MEDI4736 in combination with AZD5069
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Trial Timeline
Mar 25, 2016 → Jul 9, 2018
NCT ID
NCT02583477About MEDI4736 in combination with nab-paclitaxel and gemcitabine + MEDI4736 in combination with AZD5069
MEDI4736 in combination with nab-paclitaxel and gemcitabine + MEDI4736 in combination with AZD5069 is a phase 1/2 stage product being developed by AstraZeneca for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02583477. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Ductal Adenocarcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02583477 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma